Deep phosphoproteomics of Klebsiella pneumoniae reveals HipA-mediated tolerance to ciprofloxacin
Klebsiella pneumoniae belongs to the group of bacterial pathogens causing the majority of antibiotic-resistant nosocomial infections worldwide; however, the molecular mechanisms underlying post-translational regulation of its physiology are poorly understood. Here we perform a comprehensive analysis of Klebsiella phosphoproteome, focusing on HipA, a Ser/Thr kinase involved in antibiotic tolerance in Escherichia coli. We show that overproduced K. pneumoniae HipA (HipAkp) is toxic to both E. coli and K. pneumoniae and its toxicity can be rescued by overproduction of the antitoxin HipBkp. Importantly, HipAkp overproduction leads to increased tolerance against ciprofloxacin, a commonly used antibiotic in the treatment of K. pneumoniae infections. Proteome and phosphoproteome analyses in the absence and presence of ciprofloxacin confirm that HipAkp has Ser/Thr kinase activity, auto-phosphorylates at S150, and shares multiple substrates with HipAec, thereby providing a valuable resource to clarify the molecular basis of tolerance and the role of Ser/Thr phosphorylation in this human pathogen.
Authors
- Carsten Jers (ORCID: https://orcid.org/0000-0002-9930-3137)
- Sandra Schwarz (ORCID: https://orcid.org/0000-0001-8416-0113)
- Payal Nashier
- Ivan Mijakovic̀ (ORCID: https://orcid.org/0000-0002-8860-6853)
- Boris Maček (ORCID: https://orcid.org/0000-0002-1206-2458)
- Florian H. Ebner (ORCID: https://orcid.org/0000-0002-3409-782X)
- Michael Adler
- L Le
- Isabell Samp
- Marc Göppel
Institutions
- Novo Nordisk Foundation (DK)
- Institute of Medical Microbiology and Hygiene (DE)
- Chalmers University of Technology (SE)
- University of Tübingen (DE)
- Technical University of Denmark (DK)
Publication Details
- Journal
- PLoS Pathogens
- Published
- 2024-12-12
- DOI
- https://doi.org/10.1371/journal.ppat.1012759
- Citations
- 4
- Primary Topic
- Bacterial Genetics and Biotechnology
- Type
- article
- Field-Weighted Citation Impact
- 2.20
Funders
- International Max Planck Research School for Environmental, Cellular and Molecular Microbiology
- European Commission
- Deutsche Forschungsgemeinschaft
- Novo Nordisk
- Novo Nordisk Fonden
- Horizon 2020 Framework Programme